EGFR and non-small cell lung carcinoma: In total, less than 10% of patients received adjuvant radiation therapy (50 patients [6.9%]), and 164 patients (22.7%) underwent adjuvant platinum doublet chemotherapy, with no significant difference between EGFR-positive NSCLC and wildtype EGFR NSCLC groups.